Danaher Co. (NYSE:DHR) Shares Acquired by Alta Wealth Advisors LLC

Alta Wealth Advisors LLC increased its holdings in Danaher Co. (NYSE:DHR) by 24.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,222 shares of the conglomerate’s stock after acquiring an additional 431 shares during the quarter. Alta Wealth Advisors LLC’s holdings in Danaher were worth $618,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of DHR. Chicago Capital LLC boosted its stake in shares of Danaher by 16.5% during the third quarter. Chicago Capital LLC now owns 5,887 shares of the conglomerate’s stock worth $1,637,000 after buying an additional 835 shares during the period. TriaGen Wealth Management LLC purchased a new stake in Danaher during the 3rd quarter valued at approximately $3,624,000. Alecta Tjanstepension Omsesidigt lifted its position in Danaher by 12.3% during the 3rd quarter. Alecta Tjanstepension Omsesidigt now owns 1,208,800 shares of the conglomerate’s stock worth $335,913,000 after acquiring an additional 132,300 shares during the period. ST Germain D J Co. Inc. grew its stake in shares of Danaher by 1.6% in the 3rd quarter. ST Germain D J Co. Inc. now owns 3,125 shares of the conglomerate’s stock valued at $869,000 after purchasing an additional 48 shares during the last quarter. Finally, Schubert & Co acquired a new position in shares of Danaher in the third quarter valued at approximately $673,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Stifel Nicolaus lifted their price objective on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Robert W. Baird boosted their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Stock Performance

Shares of DHR opened at $274.38 on Friday. The company has a 50-day moving average of $270.72 and a two-hundred day moving average of $260.02. The stock has a market cap of $203.23 billion, a P/E ratio of 46.51, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 EPS. As a group, research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.